Home › Interstitial Lung Diseases › Georgia › Atlanta
Interstitial Lung Diseases clinical trials in Atlanta, GA
4 studies for Interstitial Lung Diseases are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
RecruitingPhase 3
- Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead, Atlanta
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingObservational study
- Emory University, Atlanta
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RecruitingObservational study
- Emory University, Atlanta
- Piedmont Healthcare, Austell · 15 mi away
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RecruitingPhase 3
- The Emory Clinic, Atlanta
About Interstitial Lung Diseases
Interstitial lung diseases are a group of diseases that inflame or scar the lungs. Breathing in particles (asbestosis, silicosis) causes some types.
More about Interstitial Lung Diseases on MedlinePlus
Interstitial Lung Diseases trials in other cities
- New York City, NY18 studies
- Philadelphia, PA16 studies
- Los Angeles, CA15 studies
- Kansas City, KS14 studies
- Chicago, IL13 studies
- Houston, TX13 studies
- Charleston, SC12 studies
- Durham, NC12 studies
- Aurora, CO11 studies
- Ann Arbor, MI11 studies
- Rochester, MN10 studies
- Boston, MA10 studies
Other studies in Atlanta
- Cancer (all types)50 studies
- Non-Small Cell Lung Cancer46 studies
- Breast Cancer41 studies
- Multiple Myeloma41 studies
- Prostate Cancer32 studies
- Colorectal Cancer29 studies
- Lung Cancer29 studies
- Ovarian Cancer28 studies
- Acute Myeloid Leukemia28 studies
- Obesity27 studies
- Metastatic Cancer27 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.